Canaccord Genuity cut shares of Senseonics (NYSEAMERICAN:SENS) from a buy rating to a hold rating in a research note released on Wednesday morning, The Fly reports. Canaccord Genuity currently has $1.00 price target on the stock, down from their prior price target of $2.00.

SENS has been the topic of several other research reports. Stifel Nicolaus began coverage on Senseonics in a report on Tuesday, October 22nd. They set a buy rating and a $2.00 price objective on the stock. BTIG Research restated a buy rating and set a $2.00 target price on shares of Senseonics in a research report on Sunday, August 11th. Finally, Piper Jaffray Companies set a $2.00 target price on Senseonics and gave the stock a hold rating in a research report on Wednesday, September 4th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the stock. The stock has a consensus rating of Hold and a consensus price target of $1.90.

Shares of NYSEAMERICAN SENS traded down $0.01 during mid-day trading on Wednesday, reaching $0.87. 1,516,045 shares of the company traded hands, compared to its average volume of 1,759,505. The company’s fifty day moving average is $1.07 and its two-hundred day moving average is $1.79. Senseonics has a fifty-two week low of $0.80 and a fifty-two week high of $3.60.

In related news, CEO Timothy T. Goodnow bought 88,500 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The shares were acquired at an average price of $1.10 per share, for a total transaction of $97,350.00. Corporate insiders own 34.10% of the company’s stock.

Several institutional investors have recently bought and sold shares of SENS. Bank of Montreal Can boosted its holdings in shares of Senseonics by 236.4% in the 2nd quarter. Bank of Montreal Can now owns 14,513 shares of the company’s stock valued at $29,000 after purchasing an additional 10,199 shares in the last quarter. D. E. Shaw & Co. Inc. acquired a new stake in shares of Senseonics in the 2nd quarter valued at $33,000. Centaurus Financial Inc. boosted its holdings in shares of Senseonics by 40,551.2% in the 2nd quarter. Centaurus Financial Inc. now owns 16,667 shares of the company’s stock valued at $34,000 after purchasing an additional 16,626 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Senseonics by 3.9% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 515,464 shares of the company’s stock valued at $1,052,000 after acquiring an additional 19,330 shares during the last quarter. Finally, Commonwealth Equity Services LLC lifted its stake in shares of Senseonics by 194.0% in the 3rd quarter. Commonwealth Equity Services LLC now owns 29,664 shares of the company’s stock valued at $29,000 after acquiring an additional 19,574 shares during the last quarter. 30.66% of the stock is currently owned by institutional investors.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days.

Featured Article: The risks of owning bonds

The Fly

Analyst Recommendations for Senseonics (NYSEAMERICAN:SENS)

Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.